RecruitingPhase 4NCT07295054

3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion

A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion


Sponsor

Women's College Hospital

Enrollment

110 participants

Start Date

Apr 27, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Methoxyflurane and a drug called Saline for people with iud. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethoxyflurane

3 mL of Methoxyflurane via a handheld inhaler

DRUGSaline

3 mL of Normal Saline via an identical placebo handheld inhaler


Locations(1)

Women's College Hospital

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07295054


Related Trials